
Offer oncologist-hematologists consistency in CML monitoring
BCR::ABL1 Mbcr fusion gene clinical research
When CML research applications require the quantitative detection of BCR::ABL1 Mbcr e14a2 (b3a2) & e13a2 (b2a2)fusion gene transcripts on the IS, our BCR-ABL1 Mbcr RGQ RT-PCR and ipsogen BCR-ABL1 Mbcr IS-MMR kits will deliver.
The ipsogen BCR-ABL1 Mbcr IS-MMR and ipsogen BCR-ABL1 Mbcr RGQ RT-PCR kits let you accurately monitor the molecular response on the established WHO IS in patients diagnosed with Ph+ CML.
With the kits, you get:
- Quantitative measurement of the BCR::ABL1 Mbcr fusion gene e14a2 (b3a2) & e13a2 (b2a2) transcripts in total RNA extracted from whole blood
- Direct conversion of results in every run to the established World Health Organization (WHO) IS and reporting of molecular response status
Browse our region-specific BCR::ABL1 Mbcr tests
In line with established HUGO Gene Nomenclature Committee (HGNC) recommendations for the fusion gene nomenclature (Bruford EA, et al. Leukemia. 2021, https://doi.org/10.1038/s41375-021-01436-6), we are implementing use of italics and double colon (::) for fusion genes designation (e.g. BCR::ABL1). However historical nomenclature (e.g. BCR-ABL1) may persist in our materials.